GSK PLC closed 14.69% below its 52-week high of £17.67, which the company reached on May 31st.

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

The approval of ATZUMI and BREKIYA is expected to significantly reshape the migraine market by introducing new, innovative treatment options.

Semiconductor EDA Software Market is Segmented by Type (Electronic Circuit Design and Simulation, PCB Design, IC Design), by Application (Automotive, Industrial, Consumer Electronics, Communication, ...

The dynamics of the eosinophilic esophagitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as APT-1011 (Ellodi Pharmaceuticals) ...

Inc., and Vice President at GSK plc (formerly GlaxoSmithKline plc) and Kos Pharmaceuticals, Inc. Notable achievements include building an $800M division at Kos Pharmaceuticals, Inc., helping ...

GlaxoSmithKline Consumer Nigeria Plc has announced plans to shut down its operations in the country. This was disclosed in a press statement issued on Thursday and filed with the Nigerian Exchange ...

GlaxoSmithKline Plc (GSK), a British multinational drug maker and biotechnology company, has announced its intention to end operations in Nigeria. This was made known in a statement signed by the ...

GlaxoSmithKline PLC develops and manufactures innovative vaccines and specialty medications for disease diagnosis, management, and treatment. Research and development (R&D) at GlaxoSmithKline ...

(RTTNews) - GlaxoSmithKline plc (GSK, GSK.L) announced the FDA accepted the New Drug Application for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the potential ...